NOVEL DRUG DELIVERY SYSTEMS II
|
|
|
- Norma Watkins
- 6 years ago
- Views:
Transcription
1 NOVEL DRUG DELIVERY SYSTEMS II Polymer Science 1. Define Polymer. Describe its properties. 2. Classify polymers based on various criteria. 3. What are the ideal characteristics of biodegradable polymers? Give advantages and disadvantages of biodegradable polymer in pharmaceuticals. 4. What is smart polymer? Discuss in brief giving suitable illustration. 5. Discuss the factors affecting degradation behavior of polymers. 6. Quantity of polymer can vary 1-70%, ultimate decision is from pharmacist, Comment on regulatory aspect for this. 7. Enlist various properties of polymer. Briefly describe the importance of Molecular weight and Glass Transition temperature of polymers. Discuss about the method for determination of molecular weight of polymers 8. Discuss the role of biodegradable polymers in drug delivery system and describe the mechanism of biodegradations. 9. Discuss inactive ingredient database 10. Write a note on polymers as solubilizing agents. 11. Give biodegradation mechanism of naturally occurring polymers. 12. Discuss hydrolysable polymers 13. Discuss polymers used in colon targeted drug delivery with suitable example. 14. Describe various polymers which undergo sol-gel transition. 15. Write pharmaceutical applications of polymers and discuss in brief polymer characterization. 16. Discuss in detail polymer properties.
2 Nanotechnology 1. Define nanotechnology and various products prepared by it. Explain application of nanoparticles and nanosuspensions giving examples for their market products. 2. Briefly introduce the term nanotechnology. Enlist the commonly used polymers into these products. Discuss any one method of preparation of nanoparticle. 3. Write about applications of nanoparticulate drug delivery system. 4. Give application of nanotechnology in the field of pharmaceutical science. 5. Explain the terms Nanotechnology and Nanoparticles. Enumerate different parameters and characterization methods for each parameter in context to characterization of Nanoparticulate system. Bioadhesive systems 1. Which are potential sites and dosage forms for bioadhesion? Draw a general schematic diagram for BDDS and classify them. Write a note on exvivo and in-vivo methods to study this system. 2. Discuss about theories related to Bioadhesion. 3. Discuss evaluation of bioadhesive drug delivery system. 4. Classify various factors affecting bioadhesion/mucoadhesion under separate/distinct heads and discuss in detail two factors from each head. 5. Define and explain bioadhesion, explain the theories of Bioadhesion and enumerate the properties of an ideal polymer for mucoadhesive drug delivery system Insitu gels 1. What is in-situ gel? Classify them and suggest its applications. 2. Discuss various approaches of in-situ gelation. 3. Note on: Insitu gels
3 Intelligent drug delivery systems and Tailor made medicines 1. What do you mean by intelligent DDS, explain giving suitable illustrations? 2. What is tailor-made medicine? Explain biomarker and theranostics with reference to medicine of Write about applications of hydrogel in drug delivery system. 4. Enlist various intelligent drug delivery systems. Write about the system utilizing enzymes in context to intelligent drug delivery system. 5. What is intelligent drug delivery system? Give its application 6. Write a note on tailor-made drug delivery system. 7. Discuss in detail Intelligent drug delivery Strips, diskettes and film products 1. What is diskette? Classify them and discuss in brief the methods to evaluate them. 2. Compare films/strips with TDDS; write an idea about modified TDDS. 3. Define disketts. Write a note on buccal disketts. Liposomes and Niosomes 1. Enlist materials used in preparation of liposomes. Discuss about lipid characterization and control of liposomes. Compare emulsion with liposome as a system 2. Describe in brief the structure of Niosomes. Write about method of preparation of Niosomes. 3. Define liposome. Give classification of liposome. Discuss about the characterization of liposomes. 4. Discuss the problems associated with liposomes drug delivery system. 5. Discuss Sonication and French Pressure Cell (with the help of diagram) in context to methods of preparation of liposomes. 6. Define Liposomes, classify them (based on structural parameters) and discuss the applications of the same. 7. Note on: Proniosomes
4 Ionto and Sonophoretic system 1. Define sonophoresis. Differentiate between sonophoresis and iontophoresis. Discuss about drugs used by sonophoretic drug delivery system. 2. Explain electro-osmosis and electrorepulsive with reference to Iontophoresis. 3. Give advantages of using sonophoresis as a physical penetration enhancer 4. Define Iontophoresis. Discuss advantages, disadvantages, side effects and biomedical applications of the same. 5. Note on: Historical Development of Sonophoretic system. Use of Spherical Techniques 1. What is SCF? Discuss relative features of micronization by SCF technique and its application in Pharma research. 2. How does particle geometry affect Pharma processing? Discuss conventional and novel technology of spherical techniques in brief. 3. Enlist the methods of spherical crystallization. Discuss any one method of spherical crystallization and write applications of spherical crystallization. Super and Sub-Critical fluids 1. What is SCF? State the challenges of SCF. Write about applications of SCF in pharmaceutical research. 2. Give drug delivery applications of supercritical fluid technology 3. Note on: Commonly used Super Critical fluids PEGylations 1. What is PEGylation? How will you optimize manufacturing challenges and medical application of PEG-protein? 2. Briefly explain the concept of PEGlylation. Give factors affecting performance of PEGlyted peptide. Discuss about manufacturing challenges. 3. Write a note on PEGylation. 4. Discuss in detail PEGylations
5 Biotech based products 1. Write a note on γ-dna technology. 2. Write a note on cell and gene therapy products. 3. Enumerate various techniques used to produce biotechnological products. Write about rdna technology. Give examples of FDA approved rdna products. 4. Discuss any one biotech based product in detail Proteins and Peptides 1. Proteins and peptides are vulnerable to all sorts of problems those API can face. What are the strategies for oral delivery of protein? 2. Discuss about in-vivo and in-vitro problems associated with protein and peptide. Give your comment on formulation aspects of protein and peptide delivery system. 3. Discuss issues related to delivery of proteins and peptides. 4. Discuss challenges and stability problems in context to proteins and peptides. Immunomodulated approach 1. Write a note on Immunomodulated molecules Prodrug approach 1. Define Pro-drug Discuss pathways of them in therapeutics giving suitable examples. 2. Write potential of the prodrug approach 3. Discuss in detail polymer properties.
Contents 1 Nanotechnology and Its Drug Delivery Applications
Contents 1 Nanotechnology and Its Drug Delivery Applications... 1 1.1 Introduction... 1 1.2 Historical Prospects of Nanotechnology... 2 1.3 Promising Role in Drug Delivery... 3 1.3.1 Nanoparticles and
We make drugs smarter
We make drugs smarter Brookwood Pharmaceutical Services WE MAKE DRUGS SMARTER Using our 40 years of experience, our state of the art facilities and our IP protected technologies, we leverage existing capabilities
Evonik Birmingham Laboratories
Evonik Birmingham Laboratories An integrated CDMO for advanced parenterals with a portfolio of delivery technologies, formulation development services and GMP manufacturing Evonik Birmingham Laboratories
Contents 1 Mammalian Polysacharides and Its Nanomaterials
Contents 1 Mammalian Polysacharides and Its Nanomaterials... 1 1.1 Introduction... 1 1.1.1 Polysaccharide-Based Nanoparticles... 2 1.2 Hydrophobically Modified Hyaluronic Acid... 2 1.3 Chemically Crosslinked
Advanced Biomaterials and Nanotechnologies in Drug Delivery
NANOTECHNOLOGY & ADVANCED MATERIALS SYMPOSIUM Advanced Biomaterials and Nanotechnologies in Drug Delivery Date : 25 September 2015 (Friday) Time : 2:00pm 5:00pm (Registration starts at 1:45pm) Venue :
Handbook Controlled Release Of Drugs Polymers And Aggregate Systems
Handbook Controlled Release Of Drugs Polymers And Aggregate Systems (1) The development of controlled release drug delivery system has long been a major area of bipinnata, which is used as release retardant
NanoAssemblr Benchtop. Develop Future Nanomedicines
NanoAssemblr Benchtop Develop Future Nanomedicines Develop the Future of Medicine Overcome key challenges in advancing nanomedicines: Challenges with conventional production methods Solutions with the
Transdermal Drug in Adhesive Delivery Patch
Transdermal Drug in Adhesive Delivery Patch A Technology Outline CC Lee M.Sc.,B.Sc.(Hons) CEO, Director of Technology Transdermal Drug Delivery Offers the Best of IV and Oral Administration IV Oral TDD
1201 Maryland Avenue SW, Suite 900, Washington, DC ,
1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org August 15, 2011 Dockets Management Branch (HFA-305) Food and Drug Administration 5600 Fishers Lane, Rm. 1061 Rockville,
MASTER IN PHARMACEUTICAL SCIENCES (Thesis Track)
MASTER IN PHARMACEUTICAL SCIENCES (Thesis Track) I. GENERAL RULES CONDITIONS: Plan Number 1 \ 12 70 2005 T 1. This plan conforms to the valid regulations of the programs of graduate studies. 2. Areas of
Empowering innovation.
Empowering innovation. RESOMER is a synonym for innovation and vision, enabling both pharma and medical device companies to shape and design a better future. 30 years of RESOMER The history of RESOMER
At LATITUDE, we only do one thing, and we do it very well.
Formulation Experts for Insoluble Compounds At LATITUDE, we only do one thing, and we do it very well. LATITUDE Pharmaceuticals Inc. has been tackling the most difficult drug formulation challenges for
Chapter 1. Introduction
Chapter 1 Introduction Controlled drug delivery systems, which are intended to deliver drugs at predetermined rates for predefined periods of time, have been used to overcome the shortcomings of conventional
Drug Development and Incrementally Modified Drugs : Regulatory Perspective. American Association of Pharmaceutical Scientists October 27, 2015
Drug Development and Incrementally Modified Drugs : Regulatory Perspective American Association of Pharmaceutical Scientists October 27, 2015 Larissa Lapteva, M.D., M.H.S., Division of Therapeutic Performance
FLUIDNATEK CUTTING EDGE ELECTROSPINNING & ELECTROSPRAYING DEVICES
FLUIDNATEK CUTTING EDGE ELECTROSPINNING & ELECTROSPRAYING DEVICES by THE FLUIDNATEK TOOLS we create the future USE CASES FLUIDNATEK Lab Tools are research instruments designed for the fabrication of small
Examination Assignments
Bioinformatics Institute of India BIOINFORMATICS INSTITUTE OF INDIA C-56A/28, Second Floor, Sector-62, Noida-201301, UP. INDIA Tel.: 0120-4320801 / 02, M. 09818473366, 09810535368 Email: info@bii.in, Website:
CHAPTER INTRODUCTION 1.1 ORAL DRUG DELIVERY: SCOPE AND ADVANTAGES
1.0 INTRODUCTION 1.1 ORAL DRUG DELIVERY: SCOPE AND ADVANTAGES Oral ingestion is the preferred route for administration of therapeutic agents, providing a convenient method of effectively achieving both
MARINE BIOINFORMATICS & NANOBIOTECHNOLOGY - PBBT305
MARINE BIOINFORMATICS & NANOBIOTECHNOLOGY - PBBT305 UNIT-1 MARINE GENOMICS AND PROTEOMICS 1. Define genomics? 2. Scope and functional genomics? 3. What is Genetics? 4. Define functional genomics? 5. What
Molecules and Particles as Nano- and Micro-scale Drug Carriers
Molecules and Particles as Nano- and Micro-scale Drug Carriers Last time: molecular switches Molecular railways Proteins as motors in nanodevices Today: nano- and micro-particle drug carriers Reading:
Course ADVANCED DRUG DELIVERY July 03-07, 2017 Faculty of Pharmacy Amphitheatre B Universidade de Lisboa, Portugal
PhD Programme in Medicines and Pharmaceutical Innovation Course ADVANCED DRUG DELIVERY July 03-07, 2017 Faculty of Pharmacy Amphitheatre B Universidade de Lisboa, Portugal Organizing committee at imed.ulisboa/ffulisboa
Innovative drug delivery solutions for exceptional therapeutics APIDEL2017. ALL RIGHTS RESERVED.
Innovative drug delivery solutions for exceptional therapeutics Apidel at a glance Apidel develops pharmaceutical products and provides innovative and more effective drug delivery solutions. Based on our
The research work highlights the development and evaluation of. bioavailability of drugs. The buccal route can bypass the first-pass
212 9. Summary, conclusion and recommendation 9.1 Summary and conclusion The research work highlights the development and evaluation of novel transbuccal drug antagonist of Famotidine. route have a rapid
The science of transforming an Active Pharmaceutical Ingredient (API) into a Drug Product (DP) in a specific dosage form.
The science of transforming an Active Pharmaceutical Ingredient (API) into a Drug Product (DP) in a specific dosage form. Three major needs that the formulation into a specific dosage form directly address
Polymeric hydrogels are of special importance in polymeric biomaterials because of
POLYMERIC HYDROGELS Polymeric hydrogels are of special importance in polymeric biomaterials because of their favorable biocompatibility. Hydrogels are cross-linked macromolecular networks formed by hydrophilic
UNIVERSITY OF ROME LA SAPIENZA NANOTECHNOLOGIES ENGINEERING NANOPARTICLES IN BIOMEDICINE
UNIVERSITY OF ROME LA SAPIENZA NANOTECHNOLOGIES ENGINEERING NANOPARTICLES IN BIOMEDICINE Challenges The challenges are: in-situ analysis and in vivo at micro level recognize biomolecules functionality
Nanotechnologie in der Lebensmittelindustrie
Nanotechnologie in der Lebensmittelindustrie Peter Schurtenberger Department of Physics and Fribourg Center for Nanomaterials (FriMat) University of Fribourg 1700 Fribourg, Switzerland www.unifr.ch/physics/mm/
Biopharmaceutics Applications in Drug Development
Biopharmaceutics Applications in Drug Development Edited by Rajesh Krishna Merck & Co., Inc. Rahwav, NJ. USA and Lawrence Yu Center for Drug Evaluation & Research Rockville, MD, USA 4y Springer Contents
L Intérêt du Projet CTI
L Intérêt du Projet CTI Prof. Yogeshvar N. Kalia Molecular Therapeutics Delivery Group Section des sciences pharmaceutiques CMU, 1 Rue Michel Servet, Genève Email: yogi.kalia@unige.ch REUSSIR VOS PROJETS
CHAPTER 1 INTRODUCTION AND OBJECTIVES
CHAPTER 1 INTRODUCTION AND OBJECTIVES 23 24 : Contents 1.1 Introduction... 27 1.2 Objectives of the thesis... 32 1.3 Organization of the thesis... 33 1.4 References... 35 25 26 1.1 Introduction Improving
EE 45X Biomedical Nanotechnology. Course Proposal
EE 45X Biomedical Nanotechnology 1 Introduction Jie Chen ECERF W6-019 492-9820 jchen@ece.ualberta.ca Oct. 15, 2008 The purpose of this document is to propose a new course in the area of Biomedical Nanotechnology
Types of Complex Formulations
Types of Complex Formulations Johannes Stanta on behalf of the EBF EBF Focus Workshop New Modalities and Novel Concepts in Bioanalysis Altis Grand Hotel, Lisbon - 15 to 16 May 2018 http://www.europeanbioanalysisforum.eu
Building the Europe of Knowledge
Building the Europe of Knowledge 7 th Framework Programme 2007-2013 Nanotechnology! All information preliminary! FP7 1. Capacities: Infrastructures 2. People: Erasmus, Marie-Curie 3. Ideas: ERC 4. Cooperation:
WHITE PAPER: Amorphous Solid Dispersions-One approach to improving Bioavailability
2017 WHITE PAPER: Amorphous Solid Dispersions-One approach to improving Bioavailability Eric C Buxton Clinical Associate Professor University of Wisconsin Madison School of Pharmacy, Division of Pharmacy
Centre for Bioactive Molecules and Drug Delivery (BMDD)
Centre for Bioactive Molecules and Drug Delivery (BMDD) Foreword by Prof Mak Joon Wah Professor, Dean, Postgraduate Studies & Research cum Vice-President, Research, School of Postgraduate Studies & Research
The strategy. using Atomic Force Microscope; Biomolecules and Neutraceuticals examples
The strategy for Bionanomolecules Characterizations using Atomic Force Microscope; Biomolecules and Neutraceuticals examples Dr. NagibAli Elmarzugi, PhD Head of Nanotechnology Research gp., Biotechnology
NANOPARTICLES IN BIOTECHNOLOGY, DRUG DEVELOPMENT AND DRUG DELIVERY
NANOPARTICLES IN BIOTECHNOLOGY, DRUG DEVELOPMENT AND DRUG DELIVERY BIO113B August 2014 Jackson Highsmith Project Analyst ISBN: 1-56965-904-4 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481
Issues Related to the Formulation and Delivery of Pharmaceutical Proteins
Issues Related to the Formulation and Delivery of Pharmaceutical Proteins Pretoria16 August Prof. dr. Daan J.A. Crommelin Dept. Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, UIPS Scientific
Preface... iii Contents...vii Contributors...xv. 1 Introduction to Hot-Melt Extrusion, Continuous Manufacturing: Scale-up via Hot-Melt Extrusion...
Contents Preface... iii Contents...vii Contributors...xv 1 Introduction to Hot-Melt Extrusion, Continuous Manufacturing: Scale-up via Hot-Melt Extrusion... 1 1 Background... 1 1.1 Introduction... 1 1.1.1
NANO 243/CENG 207 Course Use Only
L13: Controlled Drug Delivery Systems May 17, 2018 Introduction & Definition Controlled drug delivery systems offer an approach to regulating both the duration and spatial localization of therapeutic agents.
National Consultation on Nanomaterials and Their Implications on Human Health and Environment
National Consultation on Nanomaterials and Their Implications on Human Health and Environment Opportunities & Challenges for Nanotechnology in Food John R. Dutcher University of Guelph Nano: The Science
BIOTECHNOLOGY. Biotechnology is the process by which living organisms are used to create new products THE ORGANISMS
BIOTECHNOLOGY Biotechnology is the process by which living organisms are used to create new products THE ORGANISMS Bacteria: are prokaryotic organisms that contain circular DNA and no organelles. They
Applications of self-assembling peptides in controlled drug delivery
Applications of self-assembling peptides in controlled drug delivery Sotirios Koutsopoulos, Ph.D. Problems associated with drug administration Drug concentration in blood C toxic C effective Time 1 The
BEH.462/3.962J Molecular Principles of Biomaterials Spring 2003
Lecture 6: Biodegradable Polymers for Tissue Engineering Last time: Today: enzymatic degradation of solid polymers Engineering biological recognition of polymers Designing polymers for tissue engineering
Extrusion: Pharmaceutical Applications
Extrusion: Pharmaceutical Applications Edited by DENNIS DOUROUMIS School of Science, University UK WILEY A John Sons, Ltd., Publication List Preface 1. Extrusion: Principles 1 Keith Luker Introduction
List of E-journals Subscribed for the year 2016 (January to December) Pharmacy Faculty Sl. No.
Faculty 1 Adolescent Psychiatry Psychiatry 2 Anti Cancer Agents in Medicinal / Pharma & Quality 3 Anti-Infective Agents Pharmaceutical Microbiology 4 Anti-Inflammatory & Anti- Allergy Agents in Medicinal
INNOVATIVE TECHNOLOGY IN MEDICINE: EXPERIENCE OF POLAND AND UKRAINE
LUBLIN SCIENCE AND TECHNOLOGY PARK S.A. International research and practice conference INNOVATIVE TECHNOLOGY IN MEDICINE: EXPERIENCE OF POLAND AND UKRAINE April 28 29, 2017 Lublin, Republic of Poland 2017
Tentative Outline. Special Issue for Current Drug Delivery. Nanostructure based systems: Potential for Therapeutics, diagnostics and drug delivery
Tentative Outline Special Issue for Current Drug Delivery Nanostructure based systems: Potential for Therapeutics, diagnostics and drug delivery Guest Editor(s): Praveen Kumar Gaur 1, Shikha Mishra 2 Ghaziabad,
Biosimilars: The Impact on Academic Pharmacy
Biosimilars: The Impact on Academic Pharmacy George E. MacKinnon III, PhD, MS, RPh, FASHP Founding Dean and Professor College of Pharmacy Vice Provost for Health Sciences Roosevelt University Learning
nanoprecipitation mpeg-pla 2 nd Emulsion mpeg-pla in DCM
THERAPEUTIC NANOTECHNOLOGY LAB MODULE Location: BioNano Lab, 3119 Micro and Nanotechnology Laboratory (MNTL) Instructor: Jianjun Cheng, Assistant Professor of Materials Science and Engineering Lab Assistants:
Corporate. Established in Acquired facilities of: Competencies across the Generics & Biologics, value chain.
Established in 2013 Acquired facilities of: Corporate Enzon Pharmaceuticals- NJ, USA- 2013 Pfizer- NY, USA- 2016 Competencies across the Generics & Biologics, value chain. Contract Manufacturing Fully
Special aspects of nanomedicines: Development, manufacturing and Characterisation
Special aspects of nanomedicines: Development, manufacturing and Characterisation 1 st International Workshop on nanomedicines 2 nd September 2010 Simon Holland GlaxoSmithKline R&D, Ware, UK Simon.J.Holland@gsk.com
Controlled Release Drug Delivery from Hydrogels
Controlled Release Drug Delivery from Hydrogels Teacher s Guide Keith Neeves CSIP Graduate Fellow Cornell University 1 Overview The objective of this project is to introduce students to the concepts of
PRONANOSOME SERIES. 1. Load. 2. Shake. 3. Nanovesicles are ready to use 1-LOAD 2-SHAKE READY. Applications
CATALOGUE September 2017 Nanovex Biotechnologies is an innovative technology based spin-off founded in 2014 that provides a wide range of products and services in the nanobiotechnology field. Our specialized
BSc Biomedical Science Degree
BSc Biomedical Science Degree Overview...2 BSc Biomedical Science...3 BSc Biomedical Science Pathway...4 BSc Biomedical Science Biochemistry Pathway...5 BSc Biomedical Science Pathway...6 BSc Biomedical
Custom Antibodies & Recombinant Proteins
Custom Antibodies & Recombinant Proteins INTRODUCTION Custom services to meet your research and development requirements Improvements in health, medicine and diagnostics over the past century can be largely
Nanodiamond-Based Therapeutic Delivery Films For the Treatment of Cancer and Inflammation
Nanodiamond-Based Therapeutic Delivery Films For the Treatment of Cancer and Inflammation Dean Ho, Ph.D. Assistant Professor Departments of Biomedical and Mechanical Engineering Lurie Comprehensive Cancer
Economic Growth through Research & Innovation: The Greek Pharma Case
Economic Growth through Research & Innovation: The Greek Pharma Case Vassilios Katsos President & CEO, PHARMATHEN SA Vice President of Panhellenic Union of Pharmaceutical Industry 23 rd of April, 2015
GDUFA II Pre-ANDA Program Meetings for Complex Products
GDUFA II Pre-ANDA Program Meetings for Complex Products Robert Lionberger Director, Office of Research and Standards Office of Generic Drugs AAM Fall Technical Meeting November 7, 2017 GDUFA II Pre-ANDA
fact sheet 3 Introduction to Biosimilars & Regulatory Requirements
3 fact sheet 3 Introduction to Biosimilars & Regulatory Requirements International Alliance of Patients Organizations CAN Mezzanine 49-51 East Road London N1 6AH United Kingdom International Federation
2.3 Quantum Dots (QDs)
2.3 Quantum Dots (QDs) QDs are inorganic nanocrystals, approximately 1 10 nm in size, with unique optical properties of broad excitation, narrow size-tunable emission spectra, high photochemical stability,
Program outcomes MPHARM. Demonstrate understanding of basic sciences relevant to specialty.
Program outcomes MPHARM Upon completion of the program, student shall be able to understand: PO PO1 PO2 PO3 PO4 PO5 PO6 PO7 PO8 PO9 PO10 PO11 Demonstrate understanding of basic sciences relevant to specialty.
Content Areas of the Pharmacy Curriculum Outcomes Assessment (PCOA )
Content Areas of the Pharmacy Curriculum Outcomes Assessment (PCOA ) Area 1.0 Basic Biomedical Sciences (10%) Area 2.0 Pharmaceutical Sciences (33%) Area 3.0 Social/Behavioral/Administrative Sciences (22%)
Our Solutions for Protein Analysis
Our Solutions for Protein Analysis www.horibalifesciences.com info.sci@horiba.com Solutions for Protein Characterization Kinetics Proteins are involved in many critical roles in the body: Enzymes - allow
AIT/Athlone Institute of Technology
Technology Complete denomination: Higher Education Institute Location (city, country): Athlone, Ireland President: Prof.Ciaran O Cathain GENERAL PRESENTATION Contact person in NEWGEN: Dr. Declan Devine:
Practical Guide to Hot-Melt Extrusion: Continuous Manufacturing and Scale-up
Practical Guide to Hot-Melt Extrusion: Continuous Manufacturing and Scale-up Editor: Mohammed Maniruzzaman (C(%SM1THERS R A P R A A Smithers Group Company Shawbury, Shrewsbury, Shropshire, SY4 4NR, United
Research and Innovation in Drug Discovery and Diagnostics
INTERNATIONAL CONFERENCE Intellectual Property and Health Innovation Challenges for the future April 28, 2014, Athens, Greece Research and Innovation in Drug Discovery and Diagnostics Alexander Pintzas,
FORMULATING FOR MICRONEEDLE DELIVERY. Professor Finn Bauer
FORMULATING FOR MICRONEEDLE DELIVERY Professor Finn Bauer OVERVIEW Conventional microneedle strategies Change of mind set to consider systemic delivery of therapeutic agents Design & manufacture considerations
Healthcare. Healthcare. The Centre for Process Innovation. From innovation to commercialisation
Healthcare Healthcare The Centre for Process Innovation From innovation to commercialisation The Centre for Process Innovation From innovation to commercialisation The Centre for Process Innovation (CPI)
USP s Perspective on Drug Product Performance Test
USP s Perspective on Drug Product Performance Test Course Overview 1. The concept of in vitro dissolution Definition and application 2. Compendial dissolution/ drug release testing 3. Method development
Pharmacist Rana Musa Al-ali (Malkawi) MSc (Pharmaceutical Quality Assurance) Registration Department/JFDA
Pharmacist Rana Musa Al-ali (Malkawi) MSc (Pharmaceutical Quality Assurance) Registration Department/JFDA 1 2 ND MENA Regulatory Conference On Bioequivalence, Biowaivers, Bioanalysis, Dissolution & Biosimilars
INACTIVE INGREDIENTS DATABASE AND EMERGING DOSAGE FORMS. ExcipientFest 2016
INACTIVE INGREDIENTS DATABASE AND EMERGING DOSAGE FORMS ExcipientFest 2016 1 Presented by Meera Raghuram Manager, Global Regulatory Affairs and Strategies Lubrizol LifeSciences Chair Regulatory Affairs
Successful transfer of ligand binding assays between different laboratories
Successful transfer of ligand binding assays between different laboratories Debbie McManus Team Leader, Department of Biomarkers, Bioanalysis and Clinical Sciences 10 th EBF Open Symposium Hesperia Tower,
Advanced Pharmaceutical Manufacturing:
Advanced Pharmaceutical Manufacturing: A Perspective from the NSF Engineering Directorate Pramod P. Khargonekar Assistant Director for Engineering National Science Foundation Future of Pharmaceutical Manufacturing
GDUFA RESEARCH AND REGULATORY INITIATIVES FOR COMPLEX TOPICAL PRODUCTS
GDUFA RESEARCH AND REGULATORY INITIATIVES FOR COMPLEX TOPICAL PRODUCTS 4 th Annual Symposium on Development of Generics & 505(b)(2) Achieving Access to Complex Drug Products: Integrating Scientific and
How to Avoid Common Deficiencies in INDs and NDAs. Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER
How to Avoid Common Deficiencies in INDs and NDAs Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER 1 Structure of FDA Office of Commissioner Chief Scientist FOODS Medical Products & Tobacco
D r. M O H A M M A D H O S S A I N S H A R I A R E
D r. M O H A M M A D H O S S A I N S H A R I A R E Building- 20, Flat - 1401, Japan Garden City, Mohammadpur, Dhaka- 1207 M O B I L E - 0 1 7 1 6 6 2 0 0 1 2 E-mail: mohammad.shariare@northsouth.edu; mridul_pharmju@yahoo.com
Howida Kamal, Ph.D. Ass. Prof. of Pharmaceutics, Cairo University
Howida Kamal, Ph.D Ass. Prof. of Pharmaceutics, Cairo University Dosage forms Sterile Free from all forms of microbial life (vegetative & sporing) Free from pathogens Non-sterile Extent of total bioburden
PHARMACEUTICAL PRINCIPLES OF SOLID DOSAGE FORMS
PHARMACEUTICAL PRINCIPLES OF SOLID DOSAGE FORMS J. T. Carstensen, Ph.D. Professor of Pharmacy University of Wisconsin Madison, Wisconsin TECHNOMIC ^PUBLISHING CO.. INC J 1.ANCASTER BASET, TABLE OF CONTENTS
Emerging Drug Discovery Technologies
HEALTHCARE Emerging Drug Discovery Technologies Building competitive advantage through lab-on-a-chip, nanotechnology and RNAi By Dr. Nelesh Patel Table of Contents Dr. Nelesh Patel, B.Sc., Ph.D. Dr. Nelesh
Chapter 8 Healthcare Biotechnology
Chapter 8 Healthcare Biotechnology Outline: 8.1 Introduction 8.2 Biopharming 8.3 Models of Human Disease 8.4 Detecting and Diagnosing Human Disease 8.5 Monoclonal Antibodies 8.6 Gene Therapy 8.7 Tissue
Natassa Pippa, Stergios Pispas, Costas Demetzos
Natassa Pippa, Stergios Pispas, Costas Demetzos ILS 2015 MEETING LIPOSOME IN DRUG AND VACCINE DELIVERY 19-22 December 2015 UCL School of Pharmacy, London Fractal geometry The fractal concepts in pharmaceutical
Regulatory Issues and Drug Product Approval for Biopharmaceuticals
Regulatory Issues and Drug Product Approval for Biopharmaceuticals Vinod P. Shah, Ph. D. FIP Scientific Secretary Biotech 2007 Southern African Regional and International Regulatory Biotechnology Workshop
IN VITRO RELEASE TESTING
IN VITRO RELEASE TESTING The Issues & Challenges Involved in In Vitro Release Testing for Semi-Solid Formulations By: Qiuxi Fan, PhD; Mark Mitchnick, MD; and Andrew Loxley, PhD 62 INTRODUCTION The use
Parioforma. Pharmaceutics Landscape - summary. (formerly RM Consulting) April 2005
Parioforma (formerly RM Consulting) Pharmaceutics Landscape - summary April 2005 Parioforma Ltd 55 Princes Gate Exhibition Road South Kensington London SW7 2PN United Kingdom Tel: +44 (0) 207-225-3538
INTER CHANGEABILITY and EQUIVALENCE. Where we are and what we still have to determine!
INTER CHANGEABILITY and EQUIVALENCE Where we are and what we still have to determine! Acknowledgement Joint presentation UNICEF/MSF/ICRC Cecile Mace Jean Michel Caudron Birgit Schmauser What do we mean
Formulation and invitro evaluation of albendazole nanosuspensions
IJPAR Vol.7 Issue 2 Apr - Jun -2018 Journal Home page: ISSN:2320-2831 Research article Open Access Formulation and invitro evaluation of albendazole nanosuspensions Mothkuri Sathish Kumar Manager, Novartis
INTRODUCTION 1. INTRODUCTION
1. INTRODUCTION Helicobacter pylori (H. pylori) is reported to be an important etiologic factor in the development of the gastritis, gastric ulcer and gastric carcinoma in human stomach (Marshall and Warren,
Week 1: Discovery Biology Basic knowledge and tools used in Research and Development
Downing - Keio Summer School 2018 Healthcare and Biotechnology Course Outline page 1 Strand A: Healthcare and Biotechnology Course Outline This course aims to provide an overview of the current challenges
ADVANCES IN PHARMACEUTICAL INDUSTRY FOR WELLNESS AND SUSTAINABLE HEALTH
ADVANCES IN PHARMACEUTICAL INDUSTRY FOR WELLNESS AND SUSTAINABLE HEALTH Faculty of Pharmaceutical Sciences Chulalongkorn University Industrial pharmacy is a discipline which includes manufacturing, development,
BIOPHARMACEUTICALS Availability, Diffusion, Sustainability. Massimo Riccaboni University of Florence & CERM, Rome
BIOPHARMACEUTICALS Availability, Diffusion, Sustainability Massimo Riccaboni University of Florence & CERM, Rome The need for a precise definition of biopharmaceutical products Since the 1980s, the general
SHANGHAI MEDICILON INC.
美迪西生物医药 Integrated Preclinical Drug Discovery Services SHANGHAI MEDICILON INC. Company Profile Shanghai Medicilon Inc. is one of the top contract research organizations (CRO) in China. Since its establishment
Guidelines for Pharmaceutical Equivalence Requirements
Guidelines for Pharmaceutical Equivalence Requirements Version 1.1 1 September 2010 Page 1 of 9 Guidelines for Pharmaceutical Equivalence Requirements Version 1.1 Drug Sector Saudi Food & Drug Authority
Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing
Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Overview Serving biotech and pharma community since 1998 Proven track record of advancing small molecules from
Nano-Robotics in Medicine: An Annotated Bibliography
Hames 1 Shannon Hames Nano-Robotics in Medicine: An Annotated Bibliography Abhilash, M. "NANOROBOTS." International Journal of Pharma & Bio Sciences. 1.1 (2010): 1-10. Print. The author, a researcher of
Transdermal Drug Delivery System Regulatory Requirements (USA)
Transdermal Drug Delivery System Regulatory Requirements (USA) Vinod P. Shah, Ph. D., FIP Scientific Secretary Conference on To and Thru the Skin IPA AAPS FIP - APSTJ Mumbai, India, February 20-21, 2009
LIST OF ABBREVIATIONS
vii TABLE OF CONTENTS CHAPTER TITLE PAGE DECLARATION DEDICATION ACKNOWLEDGEMENTS ABSTRACT ABSTRAK TABLE OF CONTENTS LIST OF TABLES LIST OF FIGURES LIST OF ABBREVIATIONS LIST OF SYMBOLS LIST OF APPENDICES
Bioengineering Research in Chemical Engineering
BE.010 Spring 2005 Session #8 notes Bioengineering Research in Chemical Engineering Outline of this session: - definition of Chemical Engineering (ChE) and an overview of its undergraduate requirements
BSc BIOMEDICAL SCIENCE
Overview College of Science Biomedical Science Core March 2017 (1) BSc BIOMEDICAL SCIENCE Biomedical Science Degree 2015 1 College of Science, NUI Galway Fullscreen Next page Overview [60 credits] [60
Current Regulatory Thinking The Draft Reflection Paper On Intravenous Liposomal Product Quality Issues
Current Regulatory Thinking The Draft Reflection Paper On Intravenous Liposomal Product Quality Issues Dr. René Thürmer BfArM - and dmedical ldevices AGAH Workshop on Liposomal Formulations Bonn / 21.
Lonza Capital Markets Day Staying Ahead. Marc Funk COO Lonza Pharma & Biotech. Capital Markets Day September 2018
Corporate Lonza Capital Markets Day 2018 Staying Ahead Marc Funk COO Lonza Pharma & Biotech Staying Ahead Lonza Capital Markets Day 2018 Agenda Outlook Lonza Pharma & Biotech overview Delivering on our